A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

PHASE3CompletedINTERVENTIONAL
Enrollment

546

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

September 15, 2025

Study Completion Date

September 15, 2025

Conditions
Type 2 Diabetes
Interventions
DRUG

Orforglipron

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (70)

10310

Richmond University Medical Center, Staten Island

15683

Frontier Clinical Research, LLC, Scottdale

19114

Tristar Clinical Investigations, Philadelphia

30034

Orita Clinical Research, Decatur

33024

Encore Medical Research, Hollywood

33331

Encore Medical Research - Weston, Weston

33510

Care Access - Brandon, Brandon

38115

Lifedoc Research - Lenox Park Drive, Memphis

40503

The Research Group of Lexington, Lexington

45219

Velocity Clinical Research, Mt. Auburn, Cincinnati

50538

Centrul Medical Endocrinologie si Diabet Dr. Paveliu, Bucharest

65807

Clinvest Headlands Llc, Springfield

66606

Cotton O'Neil Diabetes & Endocrinology, Topeka

72022

SanRo Clinical Research Group, Bryant

78231

Consano Clinical Research, LLC, Shavano Park

78596

Texas Valley Clinical Research, Weslaco

83221

Bingham Memorial Hospital, Blackfoot

83702

St. Luke's Humphreys Diabetes Center: Boise, Boise

85014

Phoenix Clinical LLC, Phoenix

85286

MD First Research - Chandler, Chandler

90247

Velocity Clinical Research, Gardena, Gardena

91602

Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc., Toluca Lake

91766

Western University of Health Sciences, Pomona

92350

Loma Linda University Health System, Loma Linda

97504

Velocity Clinical Research, Medford, Medford

100051

Beijing Hospital, Beijing

210011

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

210012

Nanjing First Hospital, Nanjing

212000

Affiliated Hospital of Jiangsu University, Zhenjiang

230011

The Second People's Hospital of Hefei, Hefei

241001

Wannan Medical College Yijishan Hospital, Wuhu

250013

Jinan Central Hospital, Jinan

401147

Chongqing General Hospital, Chongqing

410147

Diabdana, Oradea

430222

CMI DNBM Dr. Pop Lavinia, Baia Mare

440055

Clinica Korall, Satu Mare

450014

The Second Affiliated Hospital of Zhengzhou University, Zhengzhou

471003

The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi

500283

C.M.D.T.A. Neomed, Brasov

540098

SC Dentosim Queen SRL - Centrul Medical Diamed, Târgu Mureş

800001

Milena Sante, Galați

800291

Diamed Obesity, Galați

29055450

CEDOES, Vitória

70200730

L2IP - Instituto de Pesquisas Clínicas, Brasília

06517

CMR of Greater New Haven, LLC, Hamden

80040-110

Quanta Diagnóstico e Terapia, Curitiba

90560-003

Insight Centro de Pesquisas, Porto Alegre

13060-803

Centro de Pesquisa Sao Lucas, Campinas

09715-090

Centro Multidisciplinar de Estudos Clinicos, São Bernardo do Campo

12243-280

ISPEM - Instituto São José dos Campos em Pesquisas Médicas, São José dos Campos

20241-180

IBPClin - Instituto Brasil de Pesquisa Clínica, Rio de Janeiro

01228-000

CPQuali Pesquisa Clínica, São Paulo

261-0004

Tokuyama Clinic, Mihama-ku,Chiba City

066-0032

Hasegawa Medical Clinic, Chitose

311-4153

MinamiAkatsukaClinic, Mito

243-0432

Matoba Internal Medicine Clinic, Ebina

247-0056

Takai Internal Medicine Clinic, Kamakura-shi

582-0005

Shiraiwa Medical Clinic, Kashihara

103-0002

The Institute of Medical Science, Asahi Life Foundation, Chuo-ku

103-0027

Tokyo-Eki Center-building Clinic, Chuo-ku

104-0031

Fukuwa Clinic, Chuo-ku

143-0015

Medical Corporation Sato Medical clinic, Ootaku

206-0633

Tama Center Clinic Mirai, Tama

862-0976

Jinnouchi Hospital, Kumamoto

553-0003

Kansai Electric Power Hospital, Osaka

870-0039

Abe Clinic, Ōita

00725

Centro de Endocrinologia y Nutricion, Caguas

00927

FDI Clinical Research, San Juan

010627

Geea Medical Easy Diet, Bucharest

013764

Centrul Medical NutriLife, Bucharest

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06109311 - A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor | Biotech Hunter | Biotech Hunter